Journal of Virus Eradication 2016; 2 (Supplement 4): 1–6
Review
Ending the epidemics of HIV, tuberculosis and malaria by 2030 is within reach, but not yet fully in our grasp.
With only 11 years left, we have no time to waste. We must step up the fight now.
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...men characteristics corresponding to the needs of end-users.
more
Die Handreichung zeigt, wie die von den Vereinten Nationen in 2015 verabschiedete Agenda 2030 mit ihren 17 globalen Zielen für nachhaltige Entwicklung (Sustainable Development Goals, SDGs) in den schulischen Unterricht integriert werden kann und leistet zugleich einen Beitrag zur Realisierung der ...in den 17 SDGs festgeschriebenen Zielsetzungen.
more
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
What We Know, What We Don’t Know, and What We Need to Do
Con esta guía de referencia rápida podrán reconocer con facilidad las enfermedades y efectos secundarios relacionados con el cambio climático, administrar los tratamientos adecuados y aconsejar a las poblaciones expuestas, presentar información actualizada sobre la relación entre los efectos s...ecundarios de ciertos medicamentos y la agravación de las dolencias sensibles al clima, y determinar las consecuencias posibles para los servicios de salud. En este libro se abordan los principales fenómenos meteorológicos, así como las afecciones en las que pueden tener incidencia, agrupados por áreas clínicas específicas.
more
This Strategic Response Plan for the measles emergency in the WHO European Region (SRP) articulates the overall status of measles resurgence in the WHO European Region and the priority actions needed to ensure an effective response to interrupt transmission, save lives and reverse the regional trend... in case numbers.
more
These guidelines are informed by evidence of ‘what works’ and lessons learned in the field. They are designed to accelerate UNICEF regional and country offices’ programming on social service workforce strengthening, and support work to better plan, develop and support the social services workf...orce with national and regional partners.
more
Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kyrgyzstan. This report provides evidence through three analyses that NCDs reduce economic outp...ut and discusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs are equivalent to 3.9% of gross domestic product. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment.
more